Vimarsana
Biggest News Aggregation in the World

Page 40 - Clinical Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Development Today - Breaking & Trending Today

Cybin Inc.: Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 - Vimarsana News

Cybin Inc.: Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

- Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 - - Ellen James, Director, Clinical Development, to present abstract titled "SPL026 (DMT fumarate) in combination

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA - Vimarsana News

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all...

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting - Vimarsana News

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

VANCOUVER, British Columbia, May 28, 2024 -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner clinical data in...

Waverley Pharma : Information circular - MarketScreener - Vimarsana News

Waverley Pharma : Information circular - MarketScreener

WAVERLEY PHARMA INC. MANAGEMENT PROXY CIRCULAR and NOTICE OF ANNUAL AND SPECIAL MEETING May 2,...

G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses - Vimarsana News

G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses

- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other...